THE FOUNDATION FOR SECURE MARKETS®

#60116

Date: November 02, 2026

Subject: Supernus Pharmaceuticals, Inc. - Contract Adjustment
Option Symbol: 11/02/2026 - SUPN remains SUPN
11/03/2026 - SUPN becomes SUPN1
Date: 11/02/2026

Contract Adjustment

Date:	November 2, 2026
Option Symbol:	11/02/2026 - SUPN remains SUPN (with adjusted deliverable described below) 11/03/2026 - SUPN changes to SUPN1
Strike Divisor:	1
Contracts Multiplier:	1
New Multiplier:	100 (e.g., a premium of 1.50 yields $150; a strike of 41 yields $4,100.00)
New Deliverable Per Contract:	1) 154 Supernus, Inc. (SUPN) Common Shares 2) Cash in lieu of 0.01 fractional SUPN shares Note: Once determined the cash in lieu of fractional share portion of the option deliverable remains fixed and does not vary with price changes of any security.
CUSIP:	(New) SUPN: 45579U109

Pricing

Until the cash in lieu amount is determined, the underlying price for SUPN1 will be determined as follows:

SUPN1 = 1.5401 (SUPN)

Delayed Settlement

The SUPN component of the SUPN1 deliverable will settle through National Securities Clearing Corporation (NSCC). OCC will delay settlement of the cash portion of the SUPN1 deliverable until the cash in lieu of

fractional SUPN shares is determined. Upon determination of the cash in lieu amount, OCC will require Put exercisers and Call assignees to deliver the appropriate cash amount.

Background

On October 15, 2026, Shareholders of Supernus Pharmaceuticals, Inc. (SUPN) voted concerning the proposed merger with Indivior Pharmaceuticals, Inc. (INDV). The merger was approved and subsequently consummated before the open on November 2, 2026. As a result, each existing SUPN Common Share will be converted into the right to receive 1.5401 INDV Common Shares. Cash will be paid in lieu of fractional INDV shares.

Following completion of the merger Indivior Pharmaceuticals, Inc. will change its name to Supernus, Inc. and the shares will be traded on Nasdaq under the trading symbol “SUPN”.

Disclaimer

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and futures and the nature of any adjustment is made by OCC pursuant to Chapter 28 (XXVIII) of OCC’s Rules. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at options@theocc.com. Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.